KYOWA KIRIN CO. LTD./ JP3256000005 /
| 10/06/2024 21:43:30 | Chg. +0.200 | Volume | Bid10/06/2024 | Ask10/06/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 16.100EUR | +1.26% | - Turnover: - |
16.000Bid Size: 154 | 16.400Ask Size: 154 | 8.65 bill.EUR | - | - |
GlobeNewswire
23/05
Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first pote...
GlobeNewswire
21/05
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapano...
GlobeNewswire
16/05
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
GlobeNewswire
08/05
Pharming Group reports first quarter 2024 financial results and provides business update
GlobeNewswire
07/05
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Ir...
GlobeNewswire
03/05
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024...
GlobeNewswire
02/05
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
02/05
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
GlobeNewswire
01/05
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Ch...
GlobeNewswire
23/04
AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval...
GlobeNewswire
10/04
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as Pr...
GlobeNewswire
25/03
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate ...
GlobeNewswire
20/03
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Ap...
